IMS Health

IMS Health was an American company that provided information, services and technology for the healthcare industry. IMS stood for Intercontinental Medical Statistics. It was the largest vendor of U.S. physician prescribing data.[2][3][4] IMS Health was founded in 1954 by Bill Frohlich and David Dubow. In 2010, IMS Health was taken private by TPG Capital, CPP Investment Board and Leonard Green & Partners.[5] The company went public on April 4, 2014 and began trading on the NYSE under the symbol IMS.[1][6] IMS Health was headquartered in Danbury, Connecticut.

Ims Health Inc.
Subsidiary
IndustryHealthcare,
Information Services, Technology
FateMerged with Quintiles to form IQVIA
SuccessorIQVIA
Founded1954 as Information Medical Statistics
HeadquartersDurham, North Carolina, USA
ProductsHealthcare Measurement, Analytics & Services, Consulting, Technology Services
Revenue$2.64B[1] (2015)
Number of employees
14,000+[1] (2015)
Websiteiqvia.com

Over 2016 Quintiles and IMS Health merged, and the resulting company was named QuintilesIMS, which was renamed to IQVIA in 2017.

Business model

IMS Health was best known for its collection of healthcare information spanning sales, de-identified prescription data, medical claims, electronic medical records[7] and social media.[8] IMS Health's products and services were used by companies to develop commercialization plans[9] and portfolio strategies,[10] to select patient and physician populations for specific therapies, and to measure the effectiveness of pharmaceutical marketing and sales resources.[11] The firm uses its own data to produce syndicated reports such as market forecasts and market intelligence.

History and acquisitions

The original name of the company was Intercontinental Marketing Statistics, hence the IMS name. IMS Health's corporate headquarters is located in Danbury, Connecticut, United States. The company's chairman and CEO is Ari Bousbib.

  • In 2002, IMS Health acquired Cambridge Pharma Consultancy, a privately held international firm that provides strategic advice to pharmaceutical management.
  • In 2003, acquired Marketing Initiatives, a specialist in healthcare facility profile data, and Data Niche Associates, a provider of rebate validation services for Medicaid and managed care.
  • In 2004, United Research China Shanghai was acquired, providing coverage of China's consumer health market.
  • In 2005, acquired PharMetrics, a U.S. provider of patient-centric integrated claims data.
  • In 2006, acquired the Life Sciences practice of Strategic Decisions Group, a portfolio strategy consultant to the life sciences industry.
  • In 2007, IMS Health acquired IHS and MedInitiatives, providers of healthcare data management analytics and technology services. That same year, ValueMedics Research was acquired, extending IMS Health's health economics and outcomes research capabilities.
  • In 2007, ranked in the Businessweek 50. This list represents "best in class" companies from the ten economic sectors that make up the S&P 500.[12]
  • In 2008, named to the World's Most Admired Companies list by Fortune. The company received the recognition again in 2010.
  • In 2008, acquired RMBC, a provider of national pharmaceutical market intelligence and analytics in Russia.
  • In 2008, acquired the Skura professional services group, based out of Mississauga, Ontario, Canada and specialized in data integration, consulting and services in business intelligence platforms to pharmaceutical and healthcare clients in North America and Europe.
  • In 2009, named to the Dow Jones Sustainability North America Index in recognition of the company's economic, environmental and social performance among the largest 600 North American companies.
  • In February 2010, IMS Health was taken private by TPG Capital, CPP Investment Board, and Leonard Green & Partners.[13]
  • In 2010, acquired Brogan, Inc., a privately held market research and consulting firm serving the Canada healthcare market.
  • In 2011, expanded its specialty and patient-level data assets in the United States with the acquisition of SDI Health. Also that year, the company acquired Ardentia Ltd in the UK, and Med-Vantage in the United States to build on its payer services in those markets.
  • In 2012, acquired PharmARC Analytic Solutions Pvt. Ltd, a Bangalore-based analytics company.
  • In 2012, acquired DecisionView, a software solutions company that helps life sciences organizations plan and track patient enrollment for clinical trials[14] and TTC,[15] a benchmarking solutions and analytics company that helps clients plan for and negotiate the costs of clinical trials. Also in 2012, the company purchased PharmaDeals Ltd.,[16] a provider of online information about business transactions, licensing, and mergers and acquisitions activity within the pharmaceutical industry.[2]
  • In 2013, acquired several companies to expand its portfolio of SaaS products: Incential Software, a provider of sales performance management technology services; 360 Vantage, which delivers multi-channel CRM software capabilities; Appature, which offers a relationship marketing platform; and Semantelli, a provider of social media analytics for the global healthcare industry.
  • In May 2015, IMS increased its software development capability by acquiring Dataline Software Ltd, a bespoke software development company and big data research specialist in the UK.[17]
  • In April 2015, IMS Health completed the purchase of Cegedim's Customer Relationship Management (CRM) software and Strategic Data business for €396 million. Cegedim acquired the software and related business when it purchased Dendrite International in 2007.[18][19]
  • In August 2015, IMS Health completed the purchase of Boston Biomedical Consultants, a provider of market data and market research covering the in vitro Diagnostics market[20]
  • In May 2016, the company announced it would merge with Quintiles[21][22] MS Health shareholders received 0.384 shares of Quintiles common stock for each share of IMS Health common stock they held, leaving the split of ownership at 51.4% IMS and 48.6% Quintiles.[23][24] The merger was completed in October and the resulting company was a $17.6 billion company called QuintilesIMS.[25] On November 6, 2017, the company adopted the new name of IQVIA.[26]

Controversy

Throughout its history, IMS Health's business of collecting anonymized pharmaceutical sales data came under scrutiny from both the media and the legal system.[27]

IMS Health v. Ayotte was a free speech case involving IMS Health.[28][29][30]

Sorrell v. IMS Health Inc. was a case about physician-data privacy, which went to the U.S. Supreme Court., the High Court ruled in favor of the company.[31][32][33][34]

gollark: Do you fear the bee machine?
gollark: Good, good.
gollark: This was an unfortunate consequence of our new waste disposal program.
gollark: I may have slightly the moon.
gollark: By drives, I mean disks.

References
  1. IMS Health Annual Report (10-K), 2014
  2. Steinbrook, R (Jun 29, 2006). "For sale: physicians' prescribing data". The New England Journal of Medicine. 354 (26): 2745–7. doi:10.1056/nejmp068125. PMID 16807410.
  3. Fugh-Berman, A (August 2008). "Prescription tracking and public health". Journal of General Internal Medicine. 23 (8): 1277–80. doi:10.1007/s11606-008-0630-0. PMC 2517975. PMID 18473146.
  4. Fugh-Berman, A; Ahari, S (April 2007). "Following the script: how drug reps make friends and influence doctors". PLOS Medicine. 4 (4): e150. doi:10.1371/journal.pmed.0040150. PMC 1876413. PMID 17455991.
  5. "IMS Health sold to TPG, CPPIB, LG&P"
  6. Picker, Leslie (2014-04-04). "TPG-Backed IMS Health Gains After $1.3 Billion Share Sale". BloombergBusiness.
  7. "What Does IMS Health Do, Anyway?". The Wall Street Journal. 5 November 2009.
  8. Munro, Dan. "New Study Ranks Johnson & Johnson #1 In Pharma For Social Media Engagement". Forbes.
  9. Drive to Develop New Commercial Models.pdf "The Drive to Develop New Commercial Models"
  10. in the News/Documents/Kleinrock, 2011 CA Biomed Industry Report_FINAL.pdf "CA Biomed Industry Report"
  11. Market Maps TL.pdf "Patient Market Maps"
  12. "The Business Week 50" Bloomberg Business Week, Accessed 20 October 2010
  13. "TPG and Pension Plan to Buy IMS Health" New York Times Deal Book, 5 November 2009
  14. "IMS Health to buy clinical trials software company DecisionView"
  15. "IMS Health Acquires TTC, Strengthening Pharma R&D Services Capabilities"
  16. "IMS Health Expands Suite of Syndicated, Web-based Analytics With Acquisition of PharmaDeals Ltd."
  17. "IMS Health Acquires Dataline Software, Extending Real-World Evidence Technology Platform and Application Suite". IMS Health. 2015-11-11. Retrieved 2017-05-25.
  18. http://www.cegedim.com/communique/Cegedim_IMS_Transaction-Closing_01-04-2015_ENG.pdf
  19. fr:Cegedim
  20. "Acquisition announcement" (PDF).
  21. Reuters (3 May 2016). "Quintiles is merging with IMS in a deal worth about $9 billion - Fortune". Fortune.
  22. "Quintiles, IMS Health Plan $9B Merger". GEN.
  23. Kristen Hallam; Zachary Tracer (3 May 2016). "IMS Health to Buy Quintiles in $9 Billion Pharma Data Deal". Bloomberg.com.
  24. Erik Holm. "Deals of the Day: IMS Health Merges With Quintiles, Biogen to Spin Off Hemophilia Arm". WSJ.
  25. Henderson, Jennifer (3 October 2016). "Quintiles, IMS Health complete merger". Triangle Business Journal, American City Business Journals. Retrieved 3 October 2016.
  26. "QuintilesIMS is now IQVIA". Business Wire. 6 November 2017. Retrieved 6 November 2017.
  27. Forbes "Company that Knows What Drugs Everyone Takes Going Public" https://www.forbes.com/sites/adamtanner/2014/01/06/company-that-knows-what-drugs-everyone-takes-going-public/
  28. Baxter, Alexander D. "IMS Health v. Ayotte: A New Direction on Commercial Speech Cases" (PDF). Berkeley Technology Law Journal. 25 (1): 649–670. Archived from the original (PDF) on 5 November 2010. Retrieved 5 February 2014.
  29. Shapiro, Ilya (28 April 2009). "IMS Health v. Ayotte | Cato Institute". cato.org. Cato Institute. Retrieved 5 February 2014.
  30. Bibet-Kalinyak, Isabelle (2012). "Critical Analysis of Sorrell v. IMS Health, Inc.: Pandora's Box at Best". Food & Drug L.J. 67: 191.
  31. "IMS Health Wins Court Attack on Vermont Marketing Law". Bloomberg. 23 November 2010.
  32. Law360 11 August, 2011. Inside Sorrell V. IMS Health
  33. Adam Liptak for the New York Times. 23 June 2011 Drug Makers Win Two Supreme Court Decisions
  34. Gayland Hethcoat Regulating Pharmaceutical Marketing After Sorrell v. IMS Health Inc. Quinnipiac Health Law Journal. 2012 Vol. 15:187
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.